Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

854 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
Hattori M, Honma N, Nagai S, Narui K, Shigechi T, Ozaki Y, Yoshida M, Sakatani T, Sasaki E, Tanabe Y, Tsurutani J, Takano T, Saji S, Masuda S, Horii R, Tsuda H, Yamaguchi R, Toyama T, Yamauchi C, Toi M, Yamamoto Y. Hattori M, et al. Among authors: sasaki e. Breast Cancer. 2024 May;31(3):335-339. doi: 10.1007/s12282-024-01550-0. Epub 2024 Mar 4. Breast Cancer. 2024. PMID: 38433181 Free PMC article.
Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes.
Terada M, Adachi Y, Sawaki M, Hattori M, Yoshimura A, Naomi G, Kotani H, Iwase M, Kataoka A, Onishi S, Sugino K, Mori M, Horisawa N, Sasaki E, Yatabe Y, Iwata H. Terada M, et al. Among authors: sasaki e. Breast Cancer Res Treat. 2018 Nov;172(1):1-7. doi: 10.1007/s10549-018-4898-4. Epub 2018 Jul 20. Breast Cancer Res Treat. 2018. PMID: 30030707 Review.
Prediction of pathological margin status using preoperative contrast-enhanced MRI in patients with early breast cancer who underwent skin-sparing mastectomy.
Kataoka A, Sawaki M, Okumura S, Onishi S, Iwase M, Sugino K, Ishiguro J, Gondo N, Kotani H, Yoshimura A, Hattori M, Sasaki E, Yatabe Y, Yoshimura K, Omi K, Iwata H. Kataoka A, et al. Among authors: sasaki e. Breast J. 2019 Mar;25(2):202-206. doi: 10.1111/tbj.13194. Epub 2019 Jan 30. Breast J. 2019. PMID: 30697867
Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study.
Tsuda H, Yoshida M, Akiyama F, Ohi Y, Kinowaki K, Kumaki N, Kondo Y, Saito A, Sasaki E, Nishimura R, Fujii S, Homma K, Horii R, Murata Y, Itami M, Kajita S, Kato H, Kurosumi M, Sakatani T, Shimizu S, Taniguchi K, Tamiya S, Nakamura H, Kanbayashi C, Shien T, Iwata H. Tsuda H, et al. Among authors: sasaki e. Jpn J Clin Oncol. 2021 Mar 3;51(3):434-443. doi: 10.1093/jjco/hyaa235. Jpn J Clin Oncol. 2021. PMID: 33420502
The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy may Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial.
Kataoka A, Sawaki M, Horisawa N, Kotani H, Yoshimura A, Hattori M, Adachi Y, Sugino K, Endo Y, Ozaki Y, Sasaki E, Hosoda W, Iwata H. Kataoka A, et al. Among authors: sasaki e. Ann Surg Oncol. 2023 Jun;30(6):3224-3232. doi: 10.1245/s10434-023-13199-8. Epub 2023 Feb 8. Ann Surg Oncol. 2023. PMID: 36754946 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36809606
854 results